Literature DB >> 8913445

Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis.

A Meier1, P Sander, K J Schaper, M Scholz, E C Böttger.   

Abstract

Quantitative susceptibility testing of clinical isolates of streptomycin-resistant Mycobacterium tuberculosis demonstrated that there is a close correlation between the molecular resistance mechanism and the in vitro activity of streptomycin: mutations in rpsL were mainly associated with high-level resistance, mutations in rrs were associated with an intermediate level of resistance, and streptomycin-resistant isolates with wild-type rpsL and rrs exhibited a low-level resistance phenotype. Investigations of streptomycin-resistant isolates with wild-type rpsL and rrs revealed that (i) there is no cross-resistance to other drugs and (ii) a permeability barrier may contribute to resistance, because resistance was significantly lowered in the presence of a membrane-active agent.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8913445      PMCID： PMC163556     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates.

Authors:  J Douglass; L M Steyn
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

Review 2.  Ribosomal drug resistance in mycobacteria.

Authors:  P Sander; A Meier; E C Böttger
Journal:  Res Microbiol       Date:  1996 Jan-Feb       Impact factor: 3.992

3.  Selective perturbation of G530 of 16 S rRNA by translational miscoding agents and a streptomycin-dependence mutation in protein S12.

Authors:  T Powers; H F Noller
Journal:  J Mol Biol       Date:  1994-01-07       Impact factor: 5.469

4.  Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance.

Authors:  A Meier; P Kirschner; F C Bange; U Vogel; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA.

Authors:  P N Allen; H F Noller
Journal:  J Mol Biol       Date:  1989-08-05       Impact factor: 5.469

6.  Streptomycin resistance in mycobacteria.

Authors:  N Honoré; S T Cole
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains.

Authors:  M S Shaila; K P Gopinathan; T Ramakrishnan
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

8.  Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study.

Authors:  B Heym; N Honoré; C Truffot-Pernot; A Banerjee; C Schurra; W R Jacobs; J D van Embden; J H Grosset; S T Cole
Journal:  Lancet       Date:  1994-07-30       Impact factor: 79.321

9.  Mechanism of antibiotic resistance in Mycobacterium intracellulare.

Authors:  Y Mizuguchi; T Udou; T Yamada
Journal:  Microbiol Immunol       Date:  1983       Impact factor: 1.955

10.  Streptomycin preferentially perturbs ribosomal proofreading.

Authors:  T Ruusala; C G Kurland
Journal:  Mol Gen Genet       Date:  1984
View more
  28 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Performance of BACTEC 960 Mycobacteria growth indicator tube in the susceptibility testing of genetically characterized Mycobacterium tuberculosis isolates.

Authors:  H J Marttila; M Marjamäki; M K Viljanen; H Soini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-06       Impact factor: 3.267

Review 3.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

4.  Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations.

Authors:  S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 5.  Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis.

Authors:  A Telenti
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

6.  Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism.

Authors:  Fernanda S Spies; Pedro E Almeida da Silva; Marta O Ribeiro; Maria Lucia Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2008-06-09       Impact factor: 5.191

7.  Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.

Authors:  Burkhard Springer; Romana C Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

8.  Aminoglycoside cross-resistance in Mycobacterium tuberculosis due to mutations in the 5' untranslated region of whiB7.

Authors:  Analise Z Reeves; Patricia J Campbell; Razvan Sultana; Seidu Malik; Megan Murray; Bonnie B Plikaytis; Thomas M Shinnick; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

Review 9.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

10.  Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Pontus Jureen; Klavdia Levina; Solomon Ghebremichael; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.